Abstract
BackgroundTo determine the effect of sodium hyaluronate combined with recombinant human epidermal growth factor (rhEGF) on clinical symptoms and inflammation in patients with newly diagnosed xerophthalmia after cataract surgery.MethodsA total of 106 patients who underwent cataract surgery and were newly diagnosed with xerophthalmia in our hospital between June 2018 and August 2019 were enrolled. Of these, 50 patients who were treated with sodium hyaluronate (0.1%) were assigned to the monotherapy group (MG) and the remaining 56 patients who were treated with sodium hyaluronate (0.1%) combined with rhEGF (20 μg/ml) were assigned to the combination group (CG). The 2 groups were compared based on ocular surface disease index (OSDI) score, break-up time (BUT), fluorescein corneal staining level, Schirmer I test (SI) level, clinical efficacy (disappearance of typical symptoms, including eyes drying, burning sensation, foreign body sensation, etc), and interleukin (IL)-1, IL-6, and tumor necrosis factor-α (TNF-α) levels. Spearman correlation analysis was conducted to analyze the relationship between IL-1, IL-6, TNF-α and clinical efficacy. In addition, receiver operating characteristic curves were drawn to analyze the predictive value of IL-1, IL-6, and TNF-α in efficacy on xerophthalmia. Results: After treatment, the CG showed reduced OSDI score compared with the MG. The CG showed increased BUT (s) and SI (mm) levels compared with MG. After treatment, the CG exhibited decreased levels of IL-1(ng/mL), IL-6 (ng/mL), and TNF-α (ng/mL) compared with the MG. Spearman correlation analysis revealed that IL-1, IL-6, and TNF-α were negatively correlated with clinical efficacy. The areas under the curves of IL-1, IL-6, and TNF-α were 0.801, 0.800, and 0.736 respectively.ConclusionsSodium hyaluronate combined with rhEGF is helpful to alleviate clinical symptoms and inflammation in patients with xerophthalmia undergoing cataract surgery.
Highlights
To determine the effect of sodium hyaluronate combined with recombinant human epidermal growth factor on clinical symptoms and inflammation in patients with newly diagnosed xerophthalmia after cataract surgery
50 patients who were treated with sodium hyaluronate were assigned to the monotherapy group (MG) and the remaining 56 patients who were treated with sodium hyaluronate combined with recombinant human epidermal growth factor (rhEGF) were assigned to the combination group (CG)
Xerophthalmia is an ocular surface disease caused by various factors, which results in instability of tear film, increase of osmotic pressure, ocular surface inflammation and injury, and nerve sensory abnormalities, and it is mainly manifested as dry eye, itching, foreign body sensation, and blurred vision [21]
Summary
To determine the effect of sodium hyaluronate combined with recombinant human epidermal growth factor (rhEGF) on clinical symptoms and inflammation in patients with newly diagnosed xerophthalmia after cataract surgery. Cataract, which affects 46 million people worldwide, is the second leading cause of blindness and visual impairment in the global population [1, 2]. Cataract is primarily treated by surgery in clinical practice. Gong et al BMC Ophthalmology (2022) 22:58 surgery has been widely used clinically and has become the treatment of choice for cataract [4]. Some patients experience xerophthalmia after surgery, which compromises the patient’s visual function and results in negative emotions, affecting the patient’s daily life and work [5, 6]. Intervention for patients with xerophthalmia after cataract surgery is crucial to improve the patient’s quality of life
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
